Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
High-risk Large B-cell Lymphoma (LBCL)
Conditions
High-risk Large B-cell Lymphoma (LBCL)
Trial Timeline
Feb 10, 2023 → Mar 1, 2031
NCT ID
NCT05605899About Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone
Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone is a phase 3 stage product being developed by Gilead Sciences for High-risk Large B-cell Lymphoma (LBCL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05605899. Target conditions include High-risk Large B-cell Lymphoma (LBCL).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05605899 | Phase 3 | Recruiting |
Competing Products
13 competing products in High-risk Large B-cell Lymphoma (LBCL)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + BCG | Merck | Phase 3 | 77 |
| Blinatumomab + Investigator's Choice Chemotherapy + Dexamethasone | Amgen | Phase 2 | 51 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Darolutamide + ADT | Bayer | Phase 2 | 49 |
| Esmolol | Baxter | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells) | ImmunityBio | Phase 2 | 49 |
| N-803 + ETBX-071 + M-CENK | ImmunityBio | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| RP2 Injection | Replimune | Phase 2 | 44 |
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | PDS Biotechnology | Phase 1 | 25 |